MeiraGTx Enters Strategic Collaboration Agreement with Eli Lilly

Nov 10, 2025

Contract Type

collaboration_agreement

BiotechnologyHealth CareGeneticsTherapeutics

Description

On November 7, 2025, MeiraGTx Holdings plc entered into a strategic collaboration and license agreement with Eli Lilly and Company. This agreement focuses on the research, development, and commercialization of genetic medicines in the ophthalmology sector. Under the terms of the agreement, MeiraGTx grants Lilly exclusive, worldwide rights for these endeavors. This collaboration seeks to advance innovative treatments for ocular diseases.

Company Information

Company

MeiraGTx Holdings plc

Location

States 450 East 29Th Street

About

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression by oral small molecules with dynamic range that can exceed 5000-fold. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring, and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: ocular diseases, including both inherited retinal diseases as well as large degenerative ocular diseases, neurodegenerative diseases, and severe forms of xerostomia. Though initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx plans to expand its focus to develop additional gene therapy treatments for patients suffering from a range of serious diseases. For more information, please visit www.meiragtx.com